Cannatrek’s Shepparton facility secures GMP accreditation, boosting export opportunities and local jobs 

Shepparton News reports that Cannatrek’s Shepparton facility has been granted Good Manufacturing Practice (GMP) accreditation by Australia’s Therapeutic Goods Administration, signalling remarkable export opportunities for its plant-based medicine operations. CEO Tommy Huppert highlighted this as a significant advancement in the plant-based medicine industry, filling a gap in the supply chain. With the intent to invest $17 million in Shepparton and forecasted creation of 70 jobs in the next three years, Cannatrek notes that GMP-compliant facilities are more likely to gain acceptance in international markets, including the United States, Europe and Asia. This Shepparton expansion focuses on cultivation, storage, and pharmaceutical-grade packaging, ensuring product quality and control.

Read more:

Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.